SG10201910896UA - Truncated von willebrand factor polypeptides for treating hemophilia - Google Patents
Truncated von willebrand factor polypeptides for treating hemophiliaInfo
- Publication number
- SG10201910896UA SG10201910896UA SG10201910896UA SG10201910896UA SG10201910896UA SG 10201910896U A SG10201910896U A SG 10201910896UA SG 10201910896U A SG10201910896U A SG 10201910896UA SG 10201910896U A SG10201910896U A SG 10201910896UA SG 10201910896U A SG10201910896U A SG 10201910896UA
- Authority
- SG
- Singapore
- Prior art keywords
- von willebrand
- willebrand factor
- treating hemophilia
- factor polypeptides
- truncated von
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15168930 | 2015-05-22 | ||
| EP16163239 | 2016-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201910896UA true SG10201910896UA (en) | 2020-01-30 |
Family
ID=56024318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201910896UA SG10201910896UA (en) | 2015-05-22 | 2016-05-20 | Truncated von willebrand factor polypeptides for treating hemophilia |
| SG11201708755WA SG11201708755WA (en) | 2015-05-22 | 2016-05-20 | Truncated von willebrand factor polypeptides for treating hemophilia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708755WA SG11201708755WA (en) | 2015-05-22 | 2016-05-20 | Truncated von willebrand factor polypeptides for treating hemophilia |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10688157B2 (en) |
| EP (1) | EP3297656B1 (en) |
| JP (1) | JP6573989B2 (en) |
| KR (1) | KR20180006453A (en) |
| CN (1) | CN107787328B (en) |
| AU (1) | AU2016266627A1 (en) |
| BR (1) | BR112017023785A2 (en) |
| CA (1) | CA2986626A1 (en) |
| DK (1) | DK3297656T3 (en) |
| ES (1) | ES2774011T3 (en) |
| IL (1) | IL255652A (en) |
| MX (1) | MX2017014503A (en) |
| RU (1) | RU2017145014A (en) |
| SG (2) | SG10201910896UA (en) |
| TW (1) | TW201713685A (en) |
| WO (1) | WO2016188907A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7252890B2 (en) * | 2016-11-11 | 2023-04-05 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Truncated von Willebrand factor polypeptides for treating hemophilia |
| IL308416B2 (en) | 2016-12-02 | 2025-08-01 | Bioverativ Therapeutics Inc | Methods for treating hemophilic arthritis using chimeric blood clotting factors |
| JP2020530436A (en) | 2017-06-22 | 2020-10-22 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Regulation of FVIII immunogenicity by truncated VWF |
| SG11202004725PA (en) | 2017-12-19 | 2020-07-29 | CSL Behring Lengnau AG | Protein purification and virus inactivation with alkyl glycosides |
| BR112020022164A2 (en) | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | methods of treating hemophilia a |
| CN110950964B (en) * | 2018-09-26 | 2021-06-18 | 安源医药科技（上海）有限公司 | Mutant single-chain human coagulation factor VIII fusion protein and preparation method and use thereof |
| KR20220029733A (en) * | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | truncated von Willebrand factor (VWF) to increase the in vitro stability of coagulation factor VIII |
| KR20250168493A (en) * | 2023-03-31 | 2025-12-02 | 옥타파마 아게 | FVIII-VWF fusion protein with improved pharmacokinetics |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| EP0793504B1 (en) | 1994-12-12 | 2005-06-08 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| ATE502958T1 (en) | 1996-04-24 | 2011-04-15 | Univ Michigan | INACTIVATION-RESISTANT FACTOR VIII |
| PT1079805E (en) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | PHARMACEUTICAL COMPOSITION UNDERSTANDING FACTOR VIII AND NEUTRAL LIPOSOMES |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| AU2002248329B2 (en) | 2001-01-12 | 2007-06-28 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
| DE60234193D1 (en) | 2001-06-14 | 2009-12-10 | Scripps Research Inst | STABILIZED FACTOR VIII WITH GENEVA CONSTRUCTED DISULPHIDE BINDINGS |
| AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| JP2005535588A (en) | 2002-04-29 | 2005-11-24 | バクスター・インターナショナル・インコーポレイテッド | Antagonists of the interaction between factor VIII and low density lipoprotein receptor-related proteins |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| DK1596887T3 (en) | 2003-02-26 | 2022-06-20 | Nektar Therapeutics | Polymer-Factor VIII conjugate |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| EP2077121B1 (en) | 2003-05-06 | 2011-02-09 | Syntonix Pharmaceuticals, Inc. | Clotting factor VII-Fc chimeric proteins for treatment of a hemostatic disorder |
| ATE525395T1 (en) | 2003-06-12 | 2011-10-15 | Lilly Co Eli | FUSION PROTEINS OF GLP-1 ANALOGS |
| CA2551916C (en) | 2003-12-31 | 2014-04-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| HRP20070268B1 (en) | 2004-11-12 | 2018-04-20 | Bayer Healthcare Llc | Site-directed modification of fviii |
| BRPI0519562A2 (en) | 2004-12-27 | 2009-01-27 | Baxter Int | proteinaceous construct, complex, method for prolonging the in vivo half-life of factor viii (fviii) or a biologically active derivative of the same pharmaceutical composition, and method for forming a proteinaceous construct |
| DE102005002444A1 (en) | 2005-01-19 | 2006-07-27 | Wella Ag | Container with a valve |
| US20110124565A1 (en) | 2005-04-14 | 2011-05-26 | Hans-Peter Hauser | Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| NZ572050A (en) | 2006-03-31 | 2011-09-30 | Baxter Int | Factor VIII conjugated to polyethylene glycol |
| ES2910207T3 (en) | 2006-06-14 | 2022-05-11 | Csl Behring Gmbh | Proteolytically Cleavable Fusion Proteins Comprising a Blood Coagulation Factor |
| EP2097096B1 (en) | 2006-12-22 | 2017-05-31 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| CA2690218C (en) * | 2007-06-13 | 2017-02-28 | Csl Behring Gmbh | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
| KR101648734B1 (en) | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
| MX2012005527A (en) | 2009-11-13 | 2012-08-08 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto. |
| ES2503890B2 (en) | 2011-06-17 | 2015-09-28 | Berry Plastics Corporation | INSULATING GLASS |
| WO2013093760A2 (en) | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| US11370827B2 (en) | 2012-01-12 | 2022-06-28 | Bioverativ Therapeutics Inc. | Chimeric factor VIII polypeptides and uses thereof |
| DK2814502T3 (en) | 2012-02-15 | 2017-12-18 | Csl Behring Gmbh | Von Willebrand Factor variants with improved Factor VIII binding affinity |
| CN104411716B (en) * | 2012-04-24 | 2018-09-07 | 诺和诺德股份有限公司 | Compounds useful in the treatment of hemophilia |
| EP2662083A1 (en) * | 2012-05-08 | 2013-11-13 | CSL Behring GmbH | Sugar compositions for treating hemophilia a and/or von willebrand disease |
| CN110054699A (en) * | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | Factor IX compound with XTEN and vWF ELISA albumen, and application thereof |
| EP3008084A2 (en) * | 2013-06-12 | 2016-04-20 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| DK3091997T5 (en) * | 2014-01-10 | 2024-10-14 | Bioverativ Therapeutics Inc | CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF |
-
2016
- 2016-05-20 SG SG10201910896UA patent/SG10201910896UA/en unknown
- 2016-05-20 ES ES16723776T patent/ES2774011T3/en active Active
- 2016-05-20 JP JP2017560682A patent/JP6573989B2/en not_active Expired - Fee Related
- 2016-05-20 KR KR1020177037156A patent/KR20180006453A/en not_active Withdrawn
- 2016-05-20 US US15/576,055 patent/US10688157B2/en active Active
- 2016-05-20 SG SG11201708755WA patent/SG11201708755WA/en unknown
- 2016-05-20 CN CN201680029650.6A patent/CN107787328B/en active Active
- 2016-05-20 AU AU2016266627A patent/AU2016266627A1/en not_active Abandoned
- 2016-05-20 DK DK16723776.7T patent/DK3297656T3/en active
- 2016-05-20 CA CA2986626A patent/CA2986626A1/en not_active Abandoned
- 2016-05-20 BR BR112017023785-7A patent/BR112017023785A2/en not_active Application Discontinuation
- 2016-05-20 EP EP16723776.7A patent/EP3297656B1/en active Active
- 2016-05-20 MX MX2017014503A patent/MX2017014503A/en unknown
- 2016-05-20 WO PCT/EP2016/061443 patent/WO2016188907A1/en not_active Ceased
- 2016-05-20 RU RU2017145014A patent/RU2017145014A/en not_active Application Discontinuation
- 2016-05-23 TW TW105116001A patent/TW201713685A/en unknown
-
2017
- 2017-11-14 IL IL255652A patent/IL255652A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10688157B2 (en) | 2020-06-23 |
| HK1250625A1 (en) | 2019-01-11 |
| CA2986626A1 (en) | 2016-12-01 |
| JP2018517691A (en) | 2018-07-05 |
| CN107787328A (en) | 2018-03-09 |
| MX2017014503A (en) | 2018-08-01 |
| WO2016188907A1 (en) | 2016-12-01 |
| US20180161402A1 (en) | 2018-06-14 |
| JP6573989B2 (en) | 2019-09-11 |
| KR20180006453A (en) | 2018-01-17 |
| CN107787328B (en) | 2021-08-06 |
| TW201713685A (en) | 2017-04-16 |
| SG11201708755WA (en) | 2017-12-28 |
| EP3297656A1 (en) | 2018-03-28 |
| EP3297656B1 (en) | 2020-01-08 |
| IL255652A (en) | 2018-01-31 |
| AU2016266627A1 (en) | 2018-01-18 |
| DK3297656T3 (en) | 2020-03-09 |
| ES2774011T3 (en) | 2020-07-16 |
| BR112017023785A2 (en) | 2018-07-17 |
| RU2017145014A (en) | 2019-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255652A (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| IL255767A (en) | Novel polypeptides | |
| ZA201802261B (en) | Polypeptides | |
| IL254907B (en) | Novel binding region containing polypeptides and their uses | |
| IL254577A0 (en) | Polypeptides | |
| PL3322544T3 (en) | Material sorting system | |
| SG10201912498YA (en) | Mutated truncated von willebrand factor | |
| IL254013A0 (en) | Novel proteins specific for pyoverdine and pyochelin | |
| HUE057115T2 (en) | Concentrate for polyester based materials | |
| IL249294A0 (en) | Preparation comprising factor viii and von willebrand factor peptides | |
| ZA201704366B (en) | Il-17a-binding polypeptides | |
| SG10201912857XA (en) | Mutated von willebrand factor | |
| SG11201706659WA (en) | Modified von willebrand factor having improved half-life | |
| GB201709222D0 (en) | C3b Inactivating Polypeptide | |
| IL255711A (en) | Methods for preparing modified von willebrand factor | |
| DK3164150T3 (en) | MODIFIED BY WILLEBRAND FACTOR | |
| SG10201912360SA (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| SG11201706657PA (en) | Compounds for improving the half-life of von willebrand factor | |
| EP3478063C0 (en) | MICROCAPSULATIONS FOR ENCAPSULATING LAMBDA-CYHALOTHRIN | |
| AU2016900034A0 (en) | Mutated truncated von willebrand factor | |
| HK1262457A1 (en) | Mutated von willebrand factor | |
| AU2016900033A0 (en) | Mutated von willebrand factor | |
| GB201617799D0 (en) | Fusion polypeptide | |
| GB201515221D0 (en) | Amphibactin-like peptides (ALPs) as anti-infective agents | |
| GB201515245D0 (en) | Novel polypeptides |